Analogic Co. (NASDAQ:ALOG) – Research analysts at Jefferies Group cut their Q3 2018 earnings estimates for shares of Analogic in a note issued to investors on Wednesday. Jefferies Group analyst A. Petrone now anticipates that the medical research company will post earnings of $0.76 per share for the quarter, down from their previous estimate of $1.00. Jefferies Group currently has a “Hold” rating and a $80.00 target price on the stock.

Several other brokerages also recently issued reports on ALOG. Zacks Investment Research raised shares of Analogic from a “hold” rating to a “buy” rating and set a $97.00 price objective on the stock in a research note on Friday, December 8th. BidaskClub downgraded shares of Analogic from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $88.33.

Shares of Analogic (NASDAQ:ALOG) traded down $1.70 on Monday, hitting $83.10. 180,700 shares of the company traded hands, compared to its average volume of 95,744. The stock has a market capitalization of $1,058.71, a P/E ratio of 43.49, a price-to-earnings-growth ratio of 4.24 and a beta of 0.86. Analogic has a fifty-two week low of $66.00 and a fifty-two week high of $88.45.

Analogic (NASDAQ:ALOG) last released its quarterly earnings results on Wednesday, December 6th. The medical research company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.43 by $0.32. The business had revenue of $106.90 million for the quarter, compared to analyst estimates of $100.55 million. Analogic had a negative net margin of 15.06% and a positive return on equity of 5.09%. The company’s quarterly revenue was down 11.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.43 earnings per share.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Teachers Advisors LLC raised its stake in Analogic by 2.5% during the first quarter. Teachers Advisors LLC now owns 26,530 shares of the medical research company’s stock worth $2,014,000 after purchasing an additional 653 shares during the period. Morgan Stanley raised its stake in Analogic by 24.5% during the first quarter. Morgan Stanley now owns 46,331 shares of the medical research company’s stock worth $3,518,000 after purchasing an additional 9,108 shares during the period. Renaissance Technologies LLC purchased a new position in Analogic during the first quarter worth approximately $1,252,000. Credit Suisse AG raised its stake in Analogic by 1.9% during the first quarter. Credit Suisse AG now owns 14,619 shares of the medical research company’s stock worth $1,109,000 after purchasing an additional 277 shares during the period. Finally, Strs Ohio raised its stake in Analogic by 6.1% during the second quarter. Strs Ohio now owns 10,400 shares of the medical research company’s stock worth $755,000 after purchasing an additional 600 shares during the period. 97.82% of the stock is currently owned by institutional investors and hedge funds.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be paid a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend is Thursday, December 14th. Analogic’s payout ratio is -6.99%.

COPYRIGHT VIOLATION NOTICE: “Analogic Co. (ALOG) Forecasted to Post Q3 2018 Earnings of $0.76 Per Share” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at

Analogic Company Profile

Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies. The Company operates through three segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography.

Earnings History and Estimates for Analogic (NASDAQ:ALOG)

Receive News & Ratings for Analogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Analogic and related companies with Analyst Ratings Network's FREE daily email newsletter.